Meeting
2013 ASCO Annual Meeting
Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.
Authors
Ritesh Patil
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
Ritesh Patil , Guy T. Clifton , Jennifer Keating Litton , Nathan M. Shumway , Timothy J Vreeland , John S. Berry IV, Alfred F Trappey III, George Earl Peoples , Elizabeth Ann Mittendorf , Sathibalan Ponniah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3096)
DOI
10.1200/jco.2013.31.15_suppl.3096
Abstract #
3096
Poster Bd #
20G
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.
First Author: A. K. Sears
Poster
2022 ASCO Annual Meeting
A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.
First Author: Snehal Patel
First Author: Snehal Patel
Poster
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
First Author: Kaitlin M. Peace